Lumexa Imaging (NASDAQ:LMRI) Stock Price Up 12.2% – Should You Buy?

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI)’s stock price traded up 12.2% during mid-day trading on Wednesday. The stock traded as high as $12.29 and last traded at $12.5850. 281,442 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 678,442 shares. The stock had previously closed at $11.22.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft set a $16.00 price objective on Lumexa Imaging in a research report on Thursday, August 13th. Truist Financial started coverage on shares of Lumexa Imaging in a report on Monday, October 5th. They issued a “buy” rating and a $18.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday, September 22nd. Barclays lifted their price target on shares of Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Friday, August 28th. Finally, Raymond James Financial set a $17.00 price objective on shares of Lumexa Imaging in a research report on Monday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $16.40.

Lumexa Imaging Price Performance

The company has a 50 day moving average of $11.12 and a 200 day moving average of $11.09. The stock has a market capitalization of $1.29 billion and a price-to-earnings ratio of -27.44. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40.

Lumexa Imaging (NASDAQ:LMRI) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, equities research analysts forecast that Lumexa Imaging Holdings, Inc. will post 0.25 EPS for the current fiscal year.

Institutional Trading of Lumexa Imaging

Several institutional investors have recently made changes to their positions in the stock. Jupiter Topco LLC purchased a new position in shares of Lumexa Imaging in the 2nd quarter valued at $24,269,000. Brooklands Fund Management Ltd acquired a new stake in Lumexa Imaging in the 3rd quarter valued at $21,577,000. Janus Henderson Group PLC increased its holdings in Lumexa Imaging by 5.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company’s stock valued at $18,063,000 after purchasing an additional 107,903 shares in the last quarter. BlackRock Inc. purchased a new position in Lumexa Imaging in the second quarter valued at about $15,771,000. Finally, Brigade Capital Management LP purchased a new stake in shares of Lumexa Imaging in the second quarter worth about $7,511,000.

About Lumexa Imaging

Lumexa Imaging is a U.S.-based provider of outpatient diagnostic imaging and radiology services. The company operates imaging centers and offers services designed to support physicians, hospitals, health systems and patients in the diagnosis and monitoring of medical conditions.

Its service portfolio includes advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound and X-ray. Lumexa also provides radiology-related services, including image interpretation and support for referring healthcare providers, through fixed-site and mobile imaging operations.

The company serves communities across the United States through its network of outpatient facilities and healthcare partnerships.